Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros








Base de dados
Intervalo de ano de publicação
1.
Neurochem Int ; 129: 104499, 2019 10.
Artigo em Inglês | MEDLINE | ID: mdl-31271766

RESUMO

Cytochrome P450 (CYP) epoxygenases and their metabolic products, epoxyeicosatrienoic acids (EETs), have been proposed as important therapeutic targets in the brain. However, CYP expression can be modified by the presence of diverse pro-inflammatory cytokines and the subsequent activation of the NF-κB pathway. It has been indicated that CYP epoxygenases are down-regulated by inflammation in the heart, kidney and liver. However, up to this point, there has been no evidence regarding regulation of CYP epoxygenases during inflammation in the brain. Therefore, in order to explore the effects of inflammation and NF-κB activation in CYP2J3 and CYP2C11 regulation, rat primary astrocytes cultures were treated with LPS with and without IMD-0354 (selective NF-κB inhibitor). Cyp2j3 and Cyp2c11 mRNA expression was determined by qRT-PCR; protein expression was determined by immunofluorescence and by Western Blot and total epoxygenase activity was determined by the quantification of EETs by ELISA. NF-κB binding sites in Cyp2j3 and Cyp2c11 promoter regions were bioinformatically predicted and Electrophoretic Mobility Shift Assays (EMSA) were performed to determine if each hypothetic response element was able to bind NF-κB complexes. Results shown that LPS treatment is able to down-regulate astrocyte CYP2J3 and CYP2C11 mRNA, protein and activity. Additionally, we have identified NK-κB as the transcription factor involved in this regulation.


Assuntos
Astrócitos/metabolismo , Regulação da Expressão Gênica , Inflamação/metabolismo , NF-kappa B/fisiologia , Animais , Hidrocarboneto de Aril Hidroxilases , Benzamidas/farmacologia , Células Cultivadas , Córtex Cerebral/citologia , Sistema Enzimático do Citocromo P-450 , Família 2 do Citocromo P450 , Regulação para Baixo/efeitos dos fármacos , Eicosanoides/biossíntese , Endotoxinas/farmacologia , Inflamação/induzido quimicamente , Inflamação/genética , Masculino , NF-kappa B/antagonistas & inibidores , Cultura Primária de Células , Regiões Promotoras Genéticas , RNA Mensageiro/biossíntese , RNA Mensageiro/genética , Ratos , Ratos Wistar , Esteroide 16-alfa-Hidroxilase , Fator de Necrose Tumoral alfa/biossíntese , Fator de Necrose Tumoral alfa/genética
2.
Drug Metab Rev ; 50(2): 95-108, 2018 05.
Artigo em Inglês | MEDLINE | ID: mdl-29451034

RESUMO

Cytochromes P450 (CYPs) constitute a family of enzymes that can be found in the endoplasmic reticulum (ER), mitochondria or the cell surface of the cells. CYPs are characterized by carrying out the oxidation of organic compounds and they are mainly recognized as mediators of the biotransformation of xenobiotics to polar hydrophilic metabolites that can be eliminated from the organism. However, these enzymes play a key role in many other physiological processes, being involved in diverse indispensable metabolic pathways since they metabolize many endogenous substrates. Various CYP isoforms are expressed in the brain, and it is believed that this could be in part due to the particular function of brain CYPs. In the brain, CYPs are involved in the cholesterol turnover, the biosynthesis of dopamine, serotonin, morphine, hormones, and protective lipid mediators (epoxyeicosatrienoic acids), in addition to their already recognized role in xenobiotics detoxification and psychotropic drug metabolism. Increasing evidence suggests that this group of enzymes is fundamental for the normal functioning and maintenance of brain homeostasis. This review is focused on highlighting the importance of CYP-mediated endogenous metabolism in the central nervous system (CNS) and its relationship with recent findings regarding CYP involvement in neurodegenerative diseases. Some therapeutic approaches focused on CYP regulation are also discussed.


Assuntos
Encéfalo/enzimologia , Sistema Enzimático do Citocromo P-450/metabolismo , Doenças Neurodegenerativas/enzimologia , Animais , Humanos , Terapia de Alvo Molecular , Doenças Neurodegenerativas/tratamento farmacológico
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA